SARS-CoV-2 Antigens |
SARS-CoV-2 Antibodies |
Sino Biological has developed a panel of mutated spike proteins to facilitate the study of these variants.
![]() |
S1+S2 | SARS-CoV-2 (2019-nCoV) Spike S1+S2 ECD-His Protein, R683A, R685A, F817P, A892P, A899P, A942P, K986P, V987P [ Expressed in HEK293 cell, bind with ACE2 ] |
|||
![]() |
S1 | SARS-CoV-2 (2019-nCoV) Spike S1 His Protein, D614G [ Expressed in HEK293 cell, bind with ACE2 ] |
![]() |
RBD | SARS-CoV-2 (2019-nCoV) Spike RBD-His Protein, Y453F [ Expressed in HEK293 cell, bind with ACE2] |
The S and N detection kits employ a standard sandwich ELISA, allowing rapid quantification of the N and S antigens. |
SARS-CoV-2 N Detection Kit (KIT40588) ![]() |
|
More about SARS-CoV-2 Antigen Detection Assay |
The S and N detection kits employ a standard sandwich ELISA, allowing rapid quantification of the N and S antigens. |
SARS-CoV-2 N Detection Kit (KIT40588) ![]() |
More about SARS-CoV-2 Antigen Detection Assay |
Sino Biological announced this week that the company has launched the world first coronavirus antigen array under its new brand SinommuneTM. This product is co-developed by Nanommune Inc., a UCI-based biotech company specializing in array technology. This antigen array is specifically designed for high throughput sero-surveillance studies of COVID-19 Coronavirus, and other virus that can lead to upper respiratory infections. The SinommuneTM is constructed by printing recombinant antigens on a nitrocellulose-coated membrane. It can analyze serum antibodies against 66 antigens from 23 types of viruses known to cause respiratory tract infections, including SARS-CoV-2 and the other six coronaviruses.
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
HCoV-OC43 | HCoV-229E | SARS-CoV | HCoV-NL63 | HCoV-HKU1 | MERS-CoV | SARS-CoV-2 |
![]() |
![]() |
![]() |
![]() |
![]() |
||
Influeza virus | RSV | Metapneumovirus | Parainfluenza | Adenovirus | ||
![]() |
![]() |
![]() |
HCoV-OC43 | HCoV-229E | SARS-CoV |
![]() |
![]() |
![]() |
HCoV-NL63 | HCoV-HKU1 | MERS-CoV |
![]() |
![]() |
![]() |
SARS-CoV-2 | Influeza virus | RSV |
![]() |
![]() |
![]() |
Metapneumovirus | Parainfluenza | Adenovirus |
SARS-CoV-2 (2019-nCoV, Novel Coronavirus 2019) has led to pneumonia (COVID-19) that sickened over 56.9M people worldwide. Same as all other coronaviruses, the genome of SARS-CoV-2 (2019-nCoV) encodes the spike protein, the envelope protein, the membrane protein, and the nucleocapsid protein.
The spike protein (S-protein) is the common target for neutralizing antibodies and vaccines. Spike protein contains two subunits, S1 and S2. S1 contains a receptor binding domain (RBD), which is responsible for recognizing and binding with the cell surface receptor. S2 subunit contains other basic elements needed for the membrane fusion. SARS-CoV-2 (2019-nCoV) (ref.) can infect the human respiratory epithelial cells through interaction with huamn ACE2. Indeed, the recombinant Spike protein can bind with recombinant ACE2 protein.
The Nucleocapsid Protein (N-protein) is the most abundant protein in coronavirus. The N-protein is a highly immunogenic phosphoprotein, and it is normally very conserved. The N protein of coronavirus is often used as a marker in diagnostic assays.
Sino Biological is the first company in the world to produce recombinant proteins of SARS-CoV-2. We launched the spike protein on Jan 22nd, only 12 days after the sequence is published. Till this day, Sino Biological has developed a large panel of reagents for COVID19 research. The available products include hundreds of antigens (the N protein, S protein, the S1 and S2 subunits of the S protein, and the RBD domain of the S proteins, Plpro, MTase, NSP3, NSP8,NSP9), monoclonal antibodies, ELISA kits, and expression vectors for SARS-CoV-2 and its receptor. These reagents have supported hundreds of research groups around the globe for their vaccine and antibody development works. Sino Biological is also offering pseudovirus-based infection assay services, allowing rapid screening of antibodies and compounds for neutralization potential.
• Xintian Xu.Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.SCIENCE CHINA Life Sciences.2020
• Bo Diao, Zeqing Feng.Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.medRxiv preprint
• 2009.5 Launched Recombinant Influenza A H5N1 Hemagglutinin Protein
• 2009.12 Launched Influenza A H5N1 HA ELISA Pair Set and H1N1 HA ELISA Pair Set
• 2012.12 Launched MERS-CoV Spike Protein(S1,S2,S-RBD),NP protein within 50 Days after Sequence Published.
• 2013.4 Completed R&D of H7N9 HA Protein & H7N9 NA Protein in 12 Days.
• 2013.10 Launched SARS CoV Spike Protein, NP Protein.
• 2014.2 Completed R&D of EBOV NP, GP, VP40, VP24 Proteins.
• 2016.6 Completed R&D of ZIKV Envelope, Membrane protein in 14 Days.
• 2020.1 Completed R&D of SARS-CoV-2 (2019-nCoV) Viral Proteins (Spike, S1, S2, RBD protein) in 12 Days.
View Related Viral Products